Nehal Gupta has a strong background in scientific research, primarily focusing on oncology. They began their work experience as a Research Assistant at Texas Tech University Health Sciences Center in 2014, where they conducted research on paclitaxel resistance in metastatic breast cancer and identified penfluridol as a potential therapeutic agent. They also screened anti-protozoal drugs for their cytotoxic effects in breast cancer cell lines.
In 2019, Gupta joined the University of California, San Francisco as a Postdoctoral Research Scientist. During their time there, they studied the cross-talk between the transcriptional repressor Capicua (CIC) and ETS-2 repressor factor (ERF) in tumor progression and metastasis. They also identified a novel subtype of prostate cancer with co-occurring ERF-CIC alterations, which had worse clinical outcomes.
Most recently, Gupta joined Nereid Therapeutics in 2022 as a Scientist in the Oncology division. Additional details about their role at Nereid Therapeutics are not provided.
Nehal Gupta's education history includes earning a Bachelor of Pharmacy (B.Pharm.) degree in Pharmaceutical Sciences from Devi Ahilya Vishwavidyalaya, which was completed from 2008 to 2012. Subsequently, Nehal completed a Master of Pharmacy degree in Pharmaceutical Sciences at B. K. mody govt. pharmacy college from 2012 to 2014. Lastly, Nehal pursued a Doctor of Philosophy (Ph.D.) degree in Cell/Cellular and Molecular Biology at Texas Tech University Health Sciences Center, which was completed from 2014 to 2019.
April, 2022 - present
Scientist, Oncology at New York Stem Cell Foundation
Associate Scientist, Oncology at New York Stem Cell Foundation
Staff Scientist, Oncology at New York Stem Cell Foundation
Scientist, Oncology at Vyro Bio
Principal Scientist Oncology at BUGWORKS Research